Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

Background and Purpose— Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation. Methods— We investigated the rate, outcomes, and predictors of ICH in 14 264 patients with atrial fibrillation from Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Cox proportional hazards modeling was used. Results— During 1.94 years (median) of follow-up, 172 patients (1.2%) experienced 175 ICH events at a rate of 0.67% per year. The significant, independent predictors of ICH were race (Asian: hazard ratio, 2.02; 95% CI, 1.39–2.94; black: hazard ratio, 3.25; 95% CI, 1.43–7.41), age (1.35; 1.13–1.63 per 10-year increase), reduced serum albumin (1.39; 1.12–1.73 per 0.5 g/dL decrease), reduced platelet count below 210×109/L (1.08; 1.02–1.13 per 10×109/L decrease), previous stroke or transient ischemic attack (1.42; 1.02–1.96), and increased diastolic blood pressure (1.17; 1.01–1.36 per 10 mm Hg increase). Predictors of a reduced risk of ICH were randomization to rivaroxaban (0.60; 0.44–0.82) and history of congestive heart failure (0.65; 0.47–0.89). The ability of the model to discriminate individuals with and without ICH was good (C-index, 0.69; 95% CI, 0.64–0.73). Conclusions— Among patients with atrial fibrillation treated with anticoagulation, the risk of ICH was higher among Asians, blacks, the elderly, and in those with previous stroke or transient ischemic attack, increased diastolic blood pressure, and reduced platelet count or serum albumin at baseline. The risk of ICH was significantly lower in patients with heart failure and in those who were randomized to rivaroxaban instead of warfarin. The external validity of these findings requires testing in other atrial fibrillation populations.

[1]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[2]  M. O’Donnell,et al.  Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation? , 2012, Stroke.

[3]  K. Butcher,et al.  Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal , 2012, Stroke.

[4]  D. Singer,et al.  Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants , 2012, Stroke.

[5]  S. Yusuf,et al.  Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial , 2012, Stroke.

[6]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[7]  S. Juvela,et al.  Effect of Increased Warfarin Use on Warfarin-Related Cerebral Hemorrhage: A Longitudinal Population-Based Study , 2011, Stroke.

[8]  W. Ageno,et al.  Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation , 2011, Circulation.

[9]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[10]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[11]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[12]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[13]  M. Flaherty.  Anticoagulant-associated intracerebral hemorrhage. , 2010, Seminars in neurology.

[14]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[15]  Carmine Zoccali,et al.  Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  R. Investigators.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.

[17]  H. Forta,et al.  Cerebral Microbleeds in Ischemic Stroke Patients on Warfarin Treatment , 2009, Stroke.

[18]  R. Abbate,et al.  Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. , 2009, Journal of the American College of Cardiology.

[19]  D. Singer,et al.  The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation , 2009, Annals of Internal Medicine.

[20]  N. Mackman.  The Role of Tissue Factor and Factor VIIa in Hemostasis , 2009, Anesthesia and analgesia.

[21]  S. Haas.  Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme , 2009, European journal of haematology.

[22]  G. Breithardt,et al.  Dilemmas in the management of atrial fibrillation in chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[23]  Steven Warach,et al.  Cerebral Microbleeds : A Field Guide to their Detection and Interpretation , 2012 .

[24]  G. Mcgwin,et al.  Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.

[25]  A. Go,et al.  Effect of Race/Ethnicity on the Efficacy of Warfarin , 2008, CNS drugs.

[26]  N. Cook.  Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. , 2008, Clinical chemistry.

[27]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[28]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[29]  A. Folsom,et al.  Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective Study , 2007, Stroke.

[30]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[31]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[32]  Wansu Chen,et al.  Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[33]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[34]  J. Broderick,et al.  The increasing incidence of anticoagulant-associated intracerebral hemorrhage , 2007, Neurology.

[35]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[36]  M. Rich,et al.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. , 2005, The American journal of medicine.

[37]  A. Algra,et al.  Risk Factors for Intracerebral Hemorrhage in the General Population: A Systematic Review , 2003, Stroke.

[38]  V. Kakkar,et al.  Blood Coagulation in Patients with Chronic Heart Failure , 2003, Drugs.

[39]  J. Szaflarski,et al.  Genetic and Environmental Risk Factors for Intracerebral Hemorrhage: Preliminary Results of a Population-Based Study , 2002, Stroke.

[40]  B. Norrving,et al.  Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy: A Swedish Multicenter Study , 2001, Stroke.

[41]  J. Gorter,et al.  Major bleeding during anticoagulation after cerebral ischemia , 1999, Neurology.

[42]  David C. Anderson,et al.  Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.

[43]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[44]  S. Rapaport,et al.  Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. , 1990, Thrombosis research.